New Oral Weight-Loss Drug Shows Superior Results to Semaglutide in Trial

A recent clinical trial indicates that orforglipron, a new once-daily oral weight-loss medication, led to greater weight reduction and improved blood sugar levels compared to oral semaglutide. Participants on orforglipron lost more weight on average and saw better HbA1c reductions. However, the trial also noted higher rates of gastrointestinal side effects with orforglipron, affecting nearly 60% of users.